Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Immunotherapy

Posts tagged ‘inflammation’

An early cell therapy product to watch out for

Credit: Silvia A Ferreira, Cristina Lopo and Eileen Gentleman, KCL

Recently a reader wrote in asking if there were any particular cell therapy products in early development that might be worth watching out for or exploring ahead of time that I would recommend following?

The approach described here fits that category nicely and also has the added bonus of potentially having multiple applications and use cases.

Some of them are in the non-oncology space too.

There were some interesting insights that emerged during this research that I thought were well worth sharing…

To learn more from our latest analysis and get a heads up on our oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

A look at an up and coming west coast biotech

With various acquisititions occurring in the wake of #JPM18 plus CAR T cell therapy being back in the news this morning following the proposed Juno acquisition by Celgene following on from the recent Kite/Gilead deal, not to mention some recent publications on the role of checkpoints in enhancing the technology, I wanted to explore a related area:

It’s time to talk about ICOS…

Before you think I’ve gone completely over to the dark side talking about blockchains, rest assured that we do not refer here to Initial Coin Offerings i.e. an unregulated means by which funds are raised for a new cryptocurrency venture, but rather to an inducible co-stimulator of T cells that is structurally and functionally related to CD28.

In short, it’s an immune stimulatory rather than inhibitory checkpoint target that is gaining attention of late and is something we are likely to hear a lot more about over the near term.

Related to this is highlighting up and coming biotechs in the IO space who are exploring novel targets beyond the obvious anti-PD(L)1 focus since we need to see what might happen with IO-IO combinations as a way to improve responses and outcomes such that more people with cancer can receive benefit from immunotherapy.

Here, we offer a look at a biotech active in this space to learn what their approach is and where their pipeline is going in the near to medium term future.

To learn more and get a heads up on our latest company interview, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

error: Content is protected !!